Throughout the month of March, all three of OSPIRG’s prescription drug bills were brought to public hearings in their respective committees. Senate Bills 763 and 764, which aim to establish transparency requirements for pharmaceutical representatives and prohibit a practice known as pay-for-delay, were considered together in the Senate Committee on Health Care on March 3rd. SB 844, which creates a Prescription Drug Affordability Board (PDAB) of experts to review expensive drug prices, came to a hearing in the same committee on March 22nd and 24th.
I watched all of these committee hearings as they were happening, and had the opportunity to listen to hours of testimony from legislators, constituents, advocates, experts, and opposition groups in regard to the three bills. Here’s a condensed version of what people had to say during the hearings:
High Value Health Care Advocate, PIRG
Maribeth educates lawmakers and the public about problems in health care and pushes for workable solutions. When she's not researching or lobbying, Maribeth likes to read, play games, and paint.